Elan and the Mayo Foundation for Medical Education and Research announced today they have made an agreement related to each other's Alzheimer's disease research efforts.
The agreement resolves a patent dispute regarding certain transgenic mice patents and facilities used by both parties.
The Elan patents involved in the dispute cover transgenic mice that express a human gene that serves an important function in the study of Alzheimer's and the development of drugs aimed at curing it.
The resolution of the dispute provides Mayo and Elan with cross-licenses necessary to pursue their respective ongoing Alzheimer's research and development efforts, and includes the ability for Mayo to conduct research with third parties.